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THE DANGER TO THE CHEMICAL WEAPONS CONVENTION FROM 
INCAPACITATING CHEMICALS 
                                                                                              
Malcolm Dando*  
Introduction 
 
1.   On 23 October 2002 a group of some 50 Chechens took over 700 people hostage in a 
Moscow theatre.  Three days later Russian forces stormed and retook the building after two 
hostages were killed.  The action by Russian forces was preceded by large quantities of 'gas' 
being pumped into the building with the intention of incapacitating the hostage-takers.  The 
hostage-takers and over 120 hostages died, and many others were hospitalised because of the 
effects of the gas.  In January 2003 some of the hostages were taking legal action against the 
authorities and complaining of persisting neurological problems.1  
 
2.  The 'gas' used was stated by the Russian Health Minister to be a derivative of fentanyl, an 
opiate chemical related to morphine,2 perhaps mixed with other agents.3  Reports suggesting 
that atropine, an antidote to anticholinergic nerve agents, did not reverse the effects of the gas 
whereas naloxone, an antidote to opiates, did supported the conclusion that a fentanyl 
derivative was used in the attempt to incapacitate the hostage-takers.4 5 
 
3.  These events and their consequences raise much wider questions about human rights than 
will be discussed here.6   In regard  to the Chemical Weapons Convention (CWC), it might, at 
first sight, appear that there is little to be discussed.  The Russian Health Minister stated that 
the hostage deaths from the gas had been the result of their weakened state and insisted that 
the Chemical Weapons Convention had not been violated.  The US President was reported to 
feel "very strongly that responsibility for this [the hostage deaths] rests with the terrorists 
who took these people hostage".7   It might also be argued that the use of an agent that was 
believed to be an anaesthetic which "could not cause death"8 falls under the "Purposes not 
                                                 
*Malcolm Dando is Professor of International Security in the Department of Peace Studies at the University of 
Bradford, Bradford, West Yorkshire, BD7 1DP, UK.  This work was supported in part by Grant Number USIP-
024-01F from the United States Institute of Peace, and project number L144250029 from the UK Economic and 
Social Research Council.  
1CBS  News.com  (2002)  Moscow Theater Victims Sue City.  Available at  http://www.cbsnews.com/stories 
/2002/10/31/world/main527614.shtml  
2CBS  News.com  (2002)  Russia IDs Theater Gas: Fentanyl. Available at  http://www.cbsnews.com/stories 
/2002/10/31/world/main527614.shtml  
3Van Damme, B. (2002)  Moscow theatre siege: a deadly gamble that nearly paid off.  The Pharmaceutical 
Journal, 269 (7224), 723-724. 
4 Fox News (2002) U.S. Questions Use of Chemical Gas. Available at  http://www.foxnews.com/story 
/0,2933,66911,00.html  
5Fox News (2002)  Gas Russia Used in Hostage Siege was Fentanyl, U.S. Officials Say.   Available at  http:// 
www.foxnews.com/story/0,2933,669,88,00.html  
6Amnesty International (AI) Index [2002] Russian Federation: Update on the situation regarding Chechens and 
in the Chechen Republic following the October hostage taking incident in Moscow.  Available at 
http://web.amnesty.org/802568F7005C4453/0/42BF43279E3E80880256C8500408F2F?Open 
7CNN.com/WORLD (2002)  Russia names Moscow siege gas.  Available at  http://europe.cnn.com/2002 
/WORLD/europe/10/30/moscow.gas/  
8CBS  News.com  (2002)  Russia IDs Theater Gas: Fentanyl. Available at  http://www.cbsnews.com/stories 
/2002/10/31/world/main527614.shtml  
 4 
Prohibited" exemption of paragraph 9 (d) of Article II of the CWC which allows use of 
chemicals for "Law enforcement including domestic riot control purposes".9 
 
4.  As with any chemical incapacitants, the concentration of fentanyl in any particular part of 
the building will have been difficult to control, the effects of any given concentration of 
fentanyl on any particularly susceptible individual would not have been known, and 
achievement of a certain separation between the incapacitating and lethal effects of the drug -
- in other words, discriminating between making people unconscious without stopping them 
breathing -- is very difficult.10  Yet it can be argued that the rescue operation in Moscow was 
a success as all of the hostages could have been killed if the Chechens had been able to use 
all the explosives they had available. 
 
5.  In the wake of the Moscow incident, other security and military forces may have analysed 
what happened in Moscow and decided that chemical incapacitants, whatever their 
limitations, could have a genuine advantage in such difficult operations.  It is well known11 
that in April 1997 the US Senate ratified the Chemical Weapons Convention with specific 
exemptions12 that would allow the use of  riot control agents in operations other than war - 
for example, to deal with mixed groups of hostile combatants and non-combatants - outside 
of domestic territory.  However, these exemptions were not tabled by the United States as 
reservations to the Convention. 
 
6.  This Review Conference Paper recognises that any such interests on the part of security 
and military agencies may have been given significant enhancement by the scientific and 
technological developments during the 1990s that might be seen to allow improved 
differentiation between the incapacitating effects of some chemical agents and their other, 
more dangerous, effects.  Clearly, if such opportunities are seen to exist, and are widely 
exploited, erosion of the General Purpose Criterion13 at the heart of the Convention is highly 
probable.  For that reason the issue of novel non-lethal chemicals cannot be ignored by the 
Review Conference which, according to paragraph 22 of Article VIII14: 
 
"...shall take into account any relevant scientific and technological developments..." 
   
7.  Fentanyl, which was discovered in the late 1950s15 and has been widely used in medicine16 
and as a drug of abuse (with numerous derivates)17, is widely known.  This Paper goes on to 
                                                 
9The Chemical Weapons Convention (text).  Available at  http://www.opcw.org/html/db/cwc/eng 
/cwc_article_II.html  
10CNN.com/WORLD (2002)  Russia names Moscow siege gas.  Available at  http://europe.cnn.com/2002 
/WORLD/europe/10/30/moscow.gas/  
11Dando, M. R. (2002)  Future incapacitating chemical agents: The impact of genomics,  pp 167-181  in N. 
Lewer (ed.), The Future of Non-Lethal Weapons.  Frank Cass, London. 
12Gordon, A (1997) Implications of the US Resolution of Ratification, CBW Conventions Bulletin, December, 
No. 38, pp. 1-6.  Available at http://fas-www.harvard.edu/~hsp.pdf.html 
13Pearson, G.S. (2003) Implementing the General Purpose Criterion of the Chemical Weapons Convention.  
First CWC Review Conference Paper No. 3, University of Bradford, January. Available at  http://www.brad. 
ac.uk/acad/scwc . 
14The Chemical Weapons Convention (text).  Available at  http://www.opcw.org/html/db/cwc/eng 
/cwc_article_VIII.html  
15Street Drugs (2003)  Fentanyl.  Available at  http://www.streetdrugs.org/fentanyl.htm  
16Medline Plus Health Information (2003)  Fentanyl.  Available at http://www.nlm.nih.gov/ 
medlineplus/druginfo/supdi/203780.html  
17Drug Facts (2003)  Street Terms: Drugs and the Drug Trade: Fentanyl.  Available at  http://www. 
whitehousedrugpolicy.gov/streetterms/ByType.asp?intTypeID=30  
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consider the recent advances in drug development and the expanded understandings of the 
effects of drugs on the body, and examines how such new knowledge might be subject to 
misuse.   Finally, consideration is given to the origin, nature and implications of paragraph 9 
(d) of Article II and what action needs to be taken by the Review Conference to ensure that 
there is no erosion of the purpose and objective of the Convention. 
 
Modern Drug Development 
 
8.  There was certainly considerable interest in the development of chemical incapacitants 
during the early and middle Cold War periods.  According to the original SIPRI study of The 
Problem of Chemical and Biological Warfare, means were sought, for example, to induce 
hypotension, emesis, alterations in body temperature, loss of balance, temporary    blindness, 
uncontrollable muscular tremors and numerous psychotropic effects.18   Whilst the 
evolutionary process had produced some chemicals with reliable effects -- for example, 
staphylococcal enterotoxin B, which is now known to overstimulate the immune system and 
thereby cause illness (and which was weaponised as an incapacitant) -- producing new 
synthetic agents remained very difficult.  Once a compound was found which had an 
interesting effect, much medicinal chemistry expertise was expended to try to enhance the 
effect by modification of this 'lead' compound.  Moreover, whilst there were many 
mechanisms by which the operation of the central nervous system could theoretically be 
disrupted, in the opinion of the SIPRI authors much more would need to be known about the 
workings of the nervous system and the actions of psychochemicals on the brain before 
effective intervention would be possible. 
 
9.  Since then, the enormous burden of unhappiness and economic costs caused by major 
mental illnesses such as inappropriate anxiety, dysregulation of mood, disturbances of 
perception and thought (psychoses), and cognitive dysfunction, in both the developed and 
developing worlds, have driven the search for new means to help the mentally ill.19 The 
serendipitous discovery of some chemical agents that were of help, in the years following the 
Second World War,20 has helped to ensure that the search for new and more effective drugs 
plays a major part in this effort.  Success in that enterprise has been greatly facilitated by the 
steadily increasing improved understanding of the brain and of the way in which drugs act 
upon it. 
 
10. Transmission of information from sense organs of the body and of information to effector 
organs, and information processing in the brain and spinal column are carried out  by 
specialised cells called neurons.  Within each neuron information is transmitted by electrical 
means (nerve impulses that can be experimentally recorded).  However, transmission of 
information between neurons and between neurons and effector organs is overwhelmingly by 
chemical means.  Junctions between neurons and between neurons and effector organs like 
muscles are called synapses.  When a nerve impulse reaches the end of a neuron it causes the 
release of a neurotransmitter chemical.  This chemical affects the post-synaptic cell in such a 
way as to either enhance the likelihood that a nerve impulse will be generated in the post-
synaptic cell (excitation) or to reduce the likelihood (inhibition).  Drugs for the treatment of 
                                                 
18SIPRI (1973)  The Problem of Chemical and Biological Warfare: Volume II CB Weapons Today.  Almqvist 
and Wiksell, Stockholm 
19World Health Organization (2001)  Mental health: New understanding, new hope.  World Health Report 
2001, World Health Organization, Geneva. 
20Barondes, S. H. (1993)  Molecules and Mental Illness.  Scientific American Library, New York.  
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mental illness have been designed to affect such processes.  As a report in 1999 by the US 
Surgeon General noted21: 
 
"Put simply, most antidepressants are designed to heighten the level of a target   
neurotransmitter at the neuronal synapse.  This can be accomplished by one or 
more of the following therapeutic actions: boosting the neurotransmitter's 
synthesis, blocking its degradation, preventing its reuptake from the synapse into 
the presynaptic neuron, or mimicking its binding to postsynaptic receptors..." 
 
Whilst there is obviously much more to learn about these processes the Surgeon General's 
report makes clear that enormous progress is being made.  In particular, the recent  
development of new means of neuroimaging has helped to elucidate which parts of the brain 
are active when certain behaviours are undertaken.  The report notes: 
 
"...Ultimately, however, the goal is not only human self-understanding.  In 
knowing eventually precisely what goes wrong in what circuits and what synapses 
and with what chemical signals, the hope is to develop treatments with greater 
effectiveness and with fewer side effects..." 
 
These laudable aims have been made much more achievable also by the revolution in our 
understanding of the human  genome - the genomics revolution. 
 
11. Most communication between neurons is through the production and reception of 
chemical signal neurotransmitters, but the reception system is complex and it is the 
elucidation of the receptors for neurotransmitters that has been facilitated by the 
genomics revolution.  The receptors for neurotransmitters are protein molecules embedded 
in the cell wall of the neuron.  The receptors are of two main types.  One type is involved in 
fast actions and the neurotransmitter binding to the receptor opens a pore in the receptor 
molecule through which ions can pass to effect change in the second nerve cell.  The second 
type is involved in slower and often more complex actions.  These slower G protein-coupled 
receptors do not operate by the neurotransmitter's binding directly opening a pore in the 
receptor molecule, but instead by the neurotransmitter interacting with the receptor to cause a 
change in the associated G protein located inside the cell wall.  The change in the G-protein 
may then initiate a variety of further changes in the cell.  The genomics revolution is crucial 
because22: 
 
"...the genome sequence information will allow us to make a short-list of proteins 
with a high probability of becoming drug targets.  In the neuroscience area, G 
protein-coupled receptors (GPCRs) and ion channels are obvious candidates 
because most existing drugs for neurologic and psychiatric diseases act on these 
classes of target..." 
 
                                                 
21Surgeon General (1999)  Mental Health: A Report of the Surgeon General.  Department of Health and Human 
Services, U.S. Public Health Service. 
22Hefti, F. (2001)  From genes to effective drugs for neurological and psychiatric diseases.  Trends in the 
Pharmacological Sciences, 22 (4), 159-60. 
 7 
Indeed, so fast has been the flow of information on GPCRs that there are now many 'orphan' 
GPCRs for which no natural neurotransmitter is currently known.  An estimate in 2001 gives 
some idea of the drug development opportunities available23: 
 
"...At present ~300 full open reading frames that encode putative members of the 
GPCR super family can be identified from the public databases.  Of these 191 are 
classified as known receptors, activated by around 70 known ligands [natural 
transmitters], and 108 are described as orphan receptors..." 
 
An idea of the dramatic rate of change in the 1990s can be gathered from analysing one 
standard source that provides annual information on receptors.  In 1990 when the source was 
first produced there were just 30 pages of information.  In 2001, in the 12th edition, this had 
expanded to 145 pages with a huge amount of detail on the many new receptor types 
discovered.24  As a consequence, a medicinal chemist is no longer 'fishing in the dark' but 
knows a great deal about the receptor structure he is trying to target with a drug - or novel 
agent. 
 
Potential Misuse? 
 
12.  The level of understanding now available to neuroscientists can be appreciated by 
considering the state of knowledge about fentanyl and its actions.  Fentanyl was first 
synthesised in Belgium in the 1950s.25  It has an analgesic potency about 80 times that of 
morphine.  It is called an opioid because of the similarity of its effects to those of morphine.26   
Fentanyl and two other related chemicals, alfentanyl and sufentanil, are widely used for 
anaesthesia and analgesia.  Over 12 different analogues of fentanyl are also used as illegal 
designer drugs.   
 
13.  Extracts from the poppy have been used to relieve pain for hundreds of years and 
morphine was first crystallised from extracts of the plant in 1803.27  Many chemical 
modifications of morphine -- for example to produce heroin, methadone and codeine -- were 
made well before the genomics era in order to try to improve the utility of the drug.  Given 
the potency of morphine, and the specificity of chemical structure required to produce its 
effects, it was proposed in the 1950s that it must be interacting with a specific receptor and in 
the 1970s endogenous peptides with similar effects were discovered.  There are now thought 
to be three classical types of opioid receptor for these peptides: ß-endorphin has strongest 
effects on µ receptors, enkephalins act most strongly at delta receptors and dynorphins at 
kappa receptors.  All these receptors are of the GPCR type.  There has also recently been the 
discovery of a structurally-related opioid-like GPCR receptor N/OFQ. Morphine and fentanyl 
exert their main actions through their effects on µ receptors28: 
 
                                                 
23Howard, A. D. et al. (2001)  Orphan G-protein-coupled receptors and natural ligand discovery. Trends in the 
Pharmacological Sciences, 22 (3), 133-140. 
24Alexander, S. et al. (2001)  TiPs Nomenclature Supplement.  Elsevier. 
25US Drug Enforcement Agency (2003)  Fentanyl.  Available at  http://www.usdoj.gov/dea/concern 
/fentanyl.html  
26Stone, T. W. (1997)  Neuropharmacology.  W. H. Freeman/Spektrum, Oxford. 
27Corbett. A., McKnight, S. and Henderson, G. (2003)  Opioid Receptors.  Available at  http://opioids.com 
/receptors/index.html  
28Stone, T. W. (1995)  Neuropharmacology.  W. H. Freeman/Spektrum, Oxford. 
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"The µ-receptors are responsible for the induction of analgesia at the level of the 
brain, but also mediate the respiratory depressant and euphoric actions of 
opioids..." 
 
14.  Rapid progress in the understanding of the circuits involved and of the pharmacology 
continues, for example through the use of 'knock-out' mice in which particular receptor types 
have been rendered non-functional.29  There is also evidence that there may be sub-types of 
the µ receptor involved in respiratory depression30 and therefore that more specifically 
targeted drugs could become available.  Additionally, as the International Union of Pure and 
Applied Chemistry has stressed, there are now techniques to develop and investigate - for 
good or ill - huge numbers of such chemicals:31 
 
"The application of automated syntheses and high throughput screening by 
pharmaceutical and agrochemical companies has produced databases of 
physiological properties associated with millions of chemical compounds..." 
 
Clearly, then, we are in a new situation in which there are incredibly rapid developments in 
our understanding of brain circuits, receptor types and sub-types, and in our ability to 
synthesise and test novel chemicals that may have effects on such receptors. 
 
15.  A straightforward test of how simple it would be to misuse such capabilities is to ask the 
following question, "In regard to neurotransmitters where there is some good reason to 
suspect that there could be interest in abuse, have chemicals with specific actions on specific 
receptor sub-types been developed?"  If this level of capability is clearly present amongst 
those striving to achieve benign results and publishing in the open literature, it is a reasonable 
supposition that those with malign purposes in mind could develop chemicals to attack such 
receptor sub-types.  Should that be the case, we necessarily have to ask what more can be 
done to prevent misuse. The next sections of this Paper show, by examination of 
developments in bioregulators and neuroscience, that this level of capability is indeed present. 
 
Bioregulators 
 
16. Although this Paper is focused primarily on the possible misuse of our growing 
understanding of the circuits, neurotransmitters and receptors of the central nervous system,   
it needs to be recognised that neurotransmitters are but one class of signalling molecules in 
the body.   Other classes that also act through cellular receptors are the hormones of the 
endocrine system and the cytokines of the immune system.  All these bioregulators are 
amongst the mid-spectrum agents covered by the prohibitions of both the Chemical Weapons 
Convention and the Biological and Toxin Weapons Convention.  Bioregulators have been 
described as32: 
 
                                                 
29Sora, I. et al. (1997)  Opiate receptor knockout mice define µ receptor roles in endogenous nociceptive   
responses and morphine-induced analgesia.  Proc. Natl. Acad. Sci., 94, 1544-1549 
30Colman, A. S. and Miller, J. H. (2001)  Modulation of breathing by µ1 and µ2 opioid receptor stimulation in 
neonatal and adult rats.   Respiratory Physiology, 127, 157-172. 
31IUPAC (2002)  Impact of Scientific Developments on the Chemical Weapons Convention.  Report to the 
Organisation for Prohibition of Chemical Weapons and its States Parties by the Union of Pure and Applied 
Chemistry.  Available at http://www.iupac.org 
32Kagan, E. (2001)  Bioregulators as instruments of terror.  Clinics in Laboratory Medicine, 21 (3), 607-618. 
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"...naturally occurring organic compounds that regulate diverse cellular 
processes in multiple organ systems.  As such, they are produced in very small 
quantities in a variety of living organisms and are essential for the normal 
homeostatic functions of the body..." 
 
They may be defined as: 
 
"...structurally diverse compounds that are capable of regulating a wide range of 
physiologic activities, such as bronchial and vascular tone, muscle contraction, 
blood pressure, heart rate, temperature and immune responses..." 
 
It is well known that the presence of such substances in unusual quantities, or in forms 
modified to alter their potency, can be extremely disruptive, leading to illness, incapacitation 
or death. 
 
17. Against that background it is not surprising to find that some of the mechanisms of 
incapacitation sought during the 20th century Cold War period could be achieved with much 
greater ease today.  One detailed review33 deals with endogenous pyrogens that cause fever, 
eicosanoids that cause bronchoconstriction and excessive mucus production in the lungs, the 
hormone insulin that can cause hypoglycemia and the blood kinin bradykinin that can cause 
hypotension.  This review is also of interest because it lists some of the advantages to an 
attacker of using bioregulators.  These include: 
 
-  non-specific effects that make diagnosis difficult; 
 
- rapid onset of action; 
 
- no vaccines available to immunize potential  victims; 
 
-  not on any threat list making detection and diagnoses very difficult; and  
 
- the possibility of unusual modes of distribution. 
 
The last point is of particular importance because the review goes on to point out the potential 
for enormously widespread consequences in using a bioregulator.  For example, if a 
bacterium was engineered to carry the gene for a dangerous cytokine in a plasmid and this 
bacterium containing the plasmid was dusted across major crops: 
 
"...If the bacterial plasmid was present in sufficiently large numbers to 
contaminate the food chain supply of a country, region, or economic zone...the 
adverse health consequences for susceptible groups of individuals could be 
considerable..."  [Emphasis added] 
 
18.  In short, it is important not to view the problem of dealing with non-lethal chemical 
agents as one solely related to tactical military actions.  Indeed, it is not difficult to find other 
ways in which such large-scale effects could be achieved - for example, in the direct 
contamination of the food or beverage supply chain in developed countries by terrorist 
groups. 
 
                                                 
33Kagan, E. (2001)  Bioregulators as instruments of terror.  Clinics in Laboratory Medicine, 21 (3), 607-618. 
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19. What has also to be understood is the range of potential abuse that will become possible 
in coming decades.  As Professor Matthew Meselson of  Harvard University has argued34:  
 
"...During the century ahead, as our ability to modify fundamental life processes 
continues its rapid advance, we will be able not only to devise additional ways to 
destroy life but will became able to manipulate it - including the processes of 
cognition, development, reproduction and inheritance..."  [Emphasis added 
 
Such developments will have profound implications.  As Meselson continued: 
 
"A world in which these capabilities are widely employed for hostile purposes 
would be a world in which the very nature of conflict had radically changed.  
Therein could lie unprecedented opportunities for violence, coercion, repression 
or subjugation..."  [Emphasis added]  
 
The threat to human rights from such a misuse of the life sciences is obvious -- particularly in 
regard to the potential for the manipulation of brain and behaviour that could lie ahead. 
 
Neuroscience 
 
20. Whilst there has been considerable concern about the impact of modern genetics on our 
society there has been a strange silence on the implications of growing capabilities in 
neuroscience.   There are some recent indications, however, of an awakening to the threats to 
civil society.  In May 2002, for example, the London Economist carried a front page 
headlined "The Future of Mind Control" and a lead article35 contrasted the great concern over 
misuse of genetics with the apparent unconcern over neuroscience: "If you want to predict 
and control a person's behaviour, the brain is the place to start".  A detailed article36 in the 
same issue  noted: 
 
"...pharmaceutical companies are only just beginning to mine the spectrum of 
psychological ailments that flesh is heir to.  Drugs to combat shyness, 
forgetfulness, sleepiness and stress are now in or close to clinical trials, not to 
mention better versions of drugs that have already swept society..." 
 
The authors expressed concern over the lack of regulatory control of such developments 
which begin to impact on the very conceptions we have of what it is to be human.   
 
21.  Such concerns were taken up by Francis Fukuyama in his book, Our Posthuman Future: 
Consequences of the Biotechnology Revolution37.  In particular, in a chapter on 
"Neuropharmacology and the Control of Behavior", he pointed out that: 
 
"...Long before genetic engineering [of human beings] becomes a possibility, 
knowledge of brain chemistry and the ability to manipulate it will become an 
important source of behavioral control that will have significant political 
                                                 
34Meselson, M. (2000)  Averting the hostile use of biology. Chemical and Biological Weapons Conventions 
Bulletin, 48 (June), 16-19. 
35Leader (2002)  The future of mind control.  The Economist, 25 May, p 11 
36Anon. (2002)  The  ethics of brain science: Open your mind.  The Economist, 25 May, 93-95. 
37Fukuyama, F. (2002)  Our Posthuman Future: Consequences of the Biotechnology Revolution.  Farrar, Straus 
and Giroux, New York. 
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implications.  We are already in the midst of this revolution and do not have to 
spin out science fiction scenarios to see how it might unfold." 
 
These authors are all concerned with the implications of the actions of those without hostile 
intent.  What then of Meselson's concerns about those with such hostile intent? 
 
22. The first neurotransmitter to be discovered, in the early 20th century, was acetylcholine.  
This would obviously also be the first target one would consider for abuse because it has been 
the prime target for modern chemical weapons.  Acetylcholine is broken down in the synapse 
by acetylcholinesterase, which limits the action of the transmitter to the appropriate level.  
The lethal nerve gases developed in the last century acted by inhibiting the function of the 
acetylcholinesterase.  Thus the synapses were inappropriately flooded with acetylcholine.  
Even minute amounts of nerve gases like tabun (GA), sarin (GB), soman (GD) and VX were 
sufficient to kill.  That much is well known.  Less well known are the considerable efforts 
that went into producing incapacitating agents which also interfered with transmission at 
acetylcholine synapses.  The United States did, in fact, weaponise one such agent called BZ -- 
3-quinuclidinyl benzilate, and Iraq is said to have a similar agent called Agent 1538.  The 
currently available drugs for treating the cognitive decline in Alzheimer's disease are also 
designed to cause a limited inhibition of acetylcholinesterase and thus to try to prevent the 
loss of acetylcholine which characterises this disease39. 
 
23. When efforts were being made to produce effective incapacitants like BZ during the Cold 
War period it was known that there were two different types of acetylcholine synapse.  
Nicotine mimics the effects of the transmitter at synapses on skeletal muscle so these 
synapses are termed nicotinic.  Muscarine, an extract from a particular type of mushroom, 
mimics the effects of the transmitter at synapses on heart muscle so these types are called 
muscarinic.  The difficulty those engaged in developing weapons in the Cold War era had 
was that they did not know what we now know, that there are nine sub-types of nicotinic and 
five sub-types of muscarinic receptor.  The muscarinic sub-types are the most important in the 
brain.  Clearly, without such knowledge, designing a reliable incapacitant was almost 
impossible and BZ was eventually rejected as too variable in its effects. 
 
24. It is known that the DNA coding sequences of the muscarinic receptors are strongly 
conserved across the evolutionary sequence of animals.  This suggests that they have very 
important functions and that if mutations occur the affected animals die out.  The range of 
functions in which muscarinic receptors are involved include the following40: 
 
"In the periphery...muscarinic receptors mediate smooth muscle contraction, 
glandular secretion, and the modulation of cardiac rate and force.  In the CNS 
[Central Nervous System], there is evidence that muscarinic receptors are 
involved in motor control, temperature regulation, cardiovascular regulation and 
memory..." 
 
                                                 
38Dando, M. R.  Future incapacitating chemical weapons: The impact of genomics.  Pp 167-181 in N. Lewer, 
(ed.), The Future of Non-Lethal Weapons: Technologies, Operations, Ethics and Law.  Frank Cass, London. 
39Bartfai, T. and Sellstrom, A. (2002)   Neurobiology, weapons, humanity.  Presentation at the ICRC   
Symposium on Biotechnology, Weapons and Humanity, Montreux, 23 September. 
40Caulfield, M. P. and Birdsall, N. J. M. (1998)  International Union of Pharmacology.  XVII. Classification of 
muscarinic acetylcholine receptors.  Pharmacological Reviews, 50 (2), 279-290. 
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Clearly, this range of functions is of considerable interest to the medical profession (for 
example, for treatment of the loss of memory in Alzheimer's disease), and pharmaceutical 
companies will make great efforts to find drugs which have controllable effects at 
acetylcholine synapses. 
 
25. Designing drugs to bind to just one of the sub-types of muscarinic receptor was 
considerably facilitated in the late 1990s when it became possible, through the use of genetic 
engineering, to breed mice lacking just one of the five different sub-types of muscarinic 
receptor.  From the investigation of such mice it became clear that the M2 receptor is one sub-
type of muscarinic receptor that functions as an inhibitory autoreceptor - as the neuron 
produces acetylcholine, the M2 receptors on that neuron are affected by it and as a 
consequence production of acetylcholine is reduced.  Thus a selective antagonist drug which 
blocked M2 receptors without affecting other types should increase the amount of 
acetylcholine available.  A contribution41 to a recent symposium on muscarinic receptor 
research described:  
 
"...the high M2 receptor selectivity of SCH72788, which has a reasonable in vivo 
activity, and, in  conscious rats, increases ACh [acetylcholine] concentrations in 
the striatum [part of the brain] and shows positive effects on a rat model of passive 
avoidance [behavioural test]..." 
 
Work on such chemicals continues in the hope of finding new means of dealing with  
Alzheimer's disease42.  However, if it is possible to design a specific antagonist to block such 
synapses, it is just as possible for those with malign intent to design a specific agonist to 
activate such receptors and close down acetylcholine production.  So instead of reducing 
cognitive deficiencies in disease one might induce them in healthy individuals -- perhaps with 
few other side-effects. 
 
26. Acetylcholine is a simple small molecule that one would intuitively think of as being 
suitable for a role as a fast-moving signalling chemical and there are others, for example 
noredrenaline. When neurotransmitters were first being discovered it was thought that a 
particular neuron would produce only one such type of 'classical' chemical transmitter.  Later 
it was discovered that there are also peptide transmitters (peptides are short strings of amino-
acids specified by a much smaller series of metabolic stages from the DNA of genes). It also 
became clear that a particular neuron can produce more than one type of neurotransmitter and 
it is often the case that a small molecule classical transmitter and a neuropeptide transmitter 
are produced by the same cell.  As for classical neurotransmitters, there are sub-types of 
receptor for the neuropeptide transmitters.  With such degrees of complexity, there are 
obviously many potential targets for new drugs or chemical agents. 
 
27. Military discussions of such neuropeptides are not often found in the open literature.  
However, an article43 entitled "An Evaluation of Bioregulators as Terrorism and Warfare 
Agents"  was published in the Applied Science and Analysis Newsletter in mid-2002.  This 
                                                 
41Birdsall, N. J. M., Nathanson, N. M. and Schwarz, R. D.  (2001)  Muscarinic receptors: It's a knockout.  
Trends in the Pharmacological Sciences, 22 (5), 215-219. 
42Lachowicz, J. E. (2002)  Selective M2 antagonists facilitate acetylcholine release and improve performance in 
behavioural models of cognition.  Presentation 115.2 in the Symposium on "Advances in Muscarinic Receptor 
Research" at the International Congress of Pharmacology, San Francisco, 7-12 July. 
43Bokan, S., Breen, J. G. and Orehovec, Z. (2002)  An evaluation of bioregulators as terrorism and warfare 
agents.  Applied Science and Analysis Newsletter, 02-3, June, 1 and 16-19. 
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article evaluated sixteen peptide bioregulators first against criteria for selection as a warfare 
agent and then against criteria for selection as a bioterrorism agent.  The criteria included the 
possibility of effective dissemination, toxicity, incapacitation, no effective prophylaxis and 
therapy, stability in the environment, difficulty of detection and identification and ease of 
production.  All sixteen bioregulators were given high cumulative scores which, the authors 
suggested, indicates that they need to be given careful consideration by experts.  In general, 
they concluded that: 
 
"...Advances in discovery of novel bioregulators, especially bioregulators for 
incapacitation, understanding of their modes of operation and synthetic routes for 
manufacture have been very rapid in recent times.  Some of these compounds may 
be potent enough to be many hundreds of times more effective than traditional 
chemical warfare agents..." 
 
How then do such neuropeptides fare against the question asked earlier -- whether selective 
synthetic agents have already been found for particular receptor sub-types.  The answer is 
again that the capability to design selective synthetic agents to target specific receptor sub-
types is already available. 
 
28. Endothelin is a 21-amino-acid chain -- a peptide -- which provides a spectacular example 
of the speed at which discoveries are being made.  Until the 1980s it was thought that the 
tissue which lines blood vessels (the endothelium) functioned only as a barrier to the passage 
of various nutrients and other substances.  It is now clear that this tissue is a widely dispersed 
'organ system' with important physiological roles.  Indeed, in the mid-1980s it was discovered 
that the cells of this endothelial tissue could release a peptide which is the most potent and 
long-lasting endogenous vasoconstrictor yet discovered -- endothelin.  Endothelin has a 
curious structure similar to that of certain snake venoms, and given its known properties, it is 
little surprise that is has been raised as an agent of potential concern in official documents 
produced during the negotiations in the 1990s on strengthening the effectiveness of the 
Biological and Toxin Weapons Convention44.  In mammals there are three endothelins, ET-1, 
ET-2 and ET-3.  ET-1 is the main vasoconstrictor in humans.   The endothelins act through 
two different GPCR sub-types, ETA and ETB.  The ETA receptor has highest affinity for ET-1 
while the ETB receptor has equal affinity for all three endothelins.  Many synthetic selective 
antagonists for ETA have been developed and both agonists and antagonists for ETB.  Under 
normal conditions endothelin is not a circulating hormone but acts locally where it is 
produced.  The bioregulator endothelin has complex functions in the regulation of blood 
pressure, development and central nervous system functions.  In the open literature its 
possible malign misuse has focused on its potential effects on the operation of the blood 
system45.  It is perhaps significant that there is already a licensed drug - bosentan - on the 
market which is a synthetic ETA/ETB antagonist used to treat high blood pressure. 
 
29. Substance P has been known since the early 1930s.  Again, it is a neuropeptide which is a 
member of a group of tachykinins comprising, in mammals, substance P, neurokinin A and 
neurokinin B.  Three GPCR receptor sub-types have been discovered so far: these  are NK1, 
NK2 and NK3.  Substance P has greatest affinity for the NK1 receptor. Substance P has many 
                                                 
44Russian Federation (1992), Illustrative List of Potential BW Agents, Ad Hoc Group of Governmental Experts 
to Identify and Examine Potential Verification Measures from a Scientific and Technical Standpoint, 
BWC/CONF.III/VEREX/WP.23, Geneva, 7 April.  Available at http://www.opbw.org 
45Hamilton, M. G. (1998)  Toxins: The emerging threat.  ASA Newsletter, 98 (3), 1 and 20-26. 
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functions, but it is of concern to biodefence authorities because it can cause intense 
bronchoconstriction.    One study46 concluded that: 
 
"Exposure to the substance at extremely low air concentrations may result in 
incapacitation in humans." 
 
The mechanism causing bronchoconstriction is complex, but synthetic antagonists to NK1 
have been tested in clinical trials in an attempt to find means of alleviating asthma.  However, 
substance P is widely distributed in the nervous system and most recently it has been of 
interest in relation to depression.  The synthetic antagonist MK-869 appears to alleviate 
depression effectively which has obviously sparked intense interest in this new route for 
helping people with such a major mental illness47. It is clearly also at least possible that an  
effective synthetic agonist could induce depression. 
 
30. An idea of the full range of present possibilities can be gained from a study carried out by 
a group in the United States known to be closely associated with the Joint Non-Lethal 
Weapons Directorate.  The study48, entitled "The Advantages and Limitations of Calmatives 
for Use as a Non-Lethal Technique" makes clear that there are other classes of compounds 
besides calmatives, such as convulsives, that could be of interest to those seeking such 
capabilities.  Calmatives are defined as agents that induce a calm or tranquil state.  Nine 
different types of neurotransmitter/receptor system are discussed in the report.  Not 
surprisingly, these include opioids and µ receptor agonists, as well as a wide range of 
classical and peptide neurotransmitters. 
 
31. According to the report: 
 
"...The researchers identified several drug classes (eg...alpha2-adrenoreceptor 
agonists) and individual drugs (...dexmedetomidine) found appropriate for 
immediate consideration as non-lethal[s]..." 
 
Such a finding is hardly surprising as the 1994 US Army Chemical and Biological Defense 
Command Edgewood RDE Center annual research conference had a paper49 which argued 
that: 
 
"Centrally acting a2-adrenergic compounds show antihypertensive actions with 
sedative properties.  More selective a2-adrenergic compounds with potent sedative 
activity have been  considered to be ideal next generation anesthetic agents which 
can be developed and used in the Less-Than-Lethal [Non-Lethal] Technology 
program..." 
 
32.  The mechanism underlying this effect is well understood.  The brain contains a rather 
small number of neurons that have the classical transmitter noradrenaline as their 
                                                 
46Koch, B. L. et al. (1999)  Inhalation of substance P and thiorphan: Acute toxicity and effects on respiration in 
conscious guinea pigs.  Journal of Applied Toxicology, 19, 19-23. 
47Kramer, M. S. et al. (1998)  Distinct mechanism for antidepressant activity by blockade of central substance P 
receptors.  Science, 281, 11 September, 1641-1645. 
48Lakoski, J. M., Bosseau Murray, W. and Renny, J. M. (2000)  The Advantages and Limitations of Calmatives 
for Use as a Non-Lethal Technique. Applied Research Laboratory, College of Medicine, Pennsylvania State 
University. 
49Chronology (1995)  15-18 November.  Chemical Weapons Convention Bulletin, 27, 16-17 
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neurotransmitter, and most of these neurons are clustered in the bilateral locus coeruleus.  
However, the nerve fibres (axons) which carry the output from these cells spread widely to 
many parts of the brain.  One recent review50 indicated the function of this system: 
 
"...In general terms...it is agreed that noradrenergic neurons influence arousal.  
This encompasses not only the sleep/waking cycle but also more specific activities, 
such as selective attention and vigilance..." 
 
Understanding the mechanisms of disruption of this system could obviously be useful in  
medicine, but also to those seeking an incapacitant.  One particular type of adrenoreceptor, 
the a2A, is an inhibitory autoreceptor on the neurons of the locus coeruleus.  Such receptors 
again function to limit the output of the locus coeruleus neurons by feedback inhibition.  The 
report notes that the drug clonidine does not have the desired effect because it also affects 
other adrenoreceptors.  However: 
 
"Dexmedetomidine acts selectively on the a2A adrenoreceptor...in the locus  
coeruleus of the central nervous system..." 
 
Dexmedetomidine was originally developed as a veterinary sedative-analgesic, but was  
released in the United States in March 2000 as an "anesthetic" for sedation of intensive  care 
patients.  It has recently been possible to generate knockout mice lacking a2A, a2B, and a2C 
adrenoreceptor sub-sub-types and to further elucidate their role.  Considerable further 
understanding of the brain's noradenaline system, and how it may be modified, is therefore to 
be expected.  
 
33. Noradrenaline is a classical small-molecule neurotransmitter.  The study of calmatives 
also deals with the neuropeptide cholecystokinin (CCK) and its receptors.  It is well known 
that there are two sub-types of CCK receptor, CCKA and CCKB.  It is also known that 
natural agonists such as the eight-amino-acid chain CCK8 can cause panic attacks in healthy 
people51.  Clearly, given the links between panic attacks and inappropriate anxiety, much 
effort has gone into developing drugs targeted at this receptor sub-type and a wide range of 
selective therapeutic agents is available52. 
 
Analysis 
 
34. The conclusion that must be reached, even from such a limited review of the many 
possibilities, is that, in regard to body systems and behaviours that could be of interest to 
those with malign intent, there is already clear evidence that specific selective agents can 
be designed to attack particular receptor sub-types.  The situation has therefore 
dramatically changed since the early Cold War period when these kinds of agents were first 
sought. 
 
35. The situation is made much more dangerous by two other factors which will become 
increasingly important in the future.  The Human Genome Project demonstrated that many of 
                                                 
50Stanford, S. C. (2001)  Noradrenaline.  Pp 163-185 in R. A. Webster (ed.), Neurotransmitters, Drugs and 
Brain Function.  John Wiley, London. 
51Noble, F. and  Roques, B. P. (1999)  CCK-B receptor: Chemistry, molecular biology, biochemistry and 
pharmacology.  Progress in Neurobiology, 58, 349-379. 
52Kopin, A. S. et al. (2000)  CCK receptor polymorphisms: An illustration of emerging themes in 
pharmacogenomics.  Trends in the Pharmacological Sciences, 21, September, 346-353. 
 16 
the relatively small number of genes that separate us from other animals are involved in 
neural development, structure and function53. Moreover, the number of genetic diseases 
affecting the nervous system is higher than for any other organ system54, and many of these 
diseases are caused by defects in transmitter/receptor systems.  For example, there are 
differences relating to the ability to deal with acetylcholinesterase inhibitors55.  Whilst no 
such polymorphism (difference in genetic constitution) has yet been found to occur 
exclusively in one ethnic group, big differences are known between groups and this gives rise 
to fears of misuse56.  Secondly, one area of intense work on gene therapy is in relation to 
dealing with brain  tumours.57  Such techniques will undoubtedly improve and there are well-
known examples of viruses which specifically target the nervous system which might be used 
in treatment.  The group of arboviruses (viruses transmitted naturally by arthropods), for 
example, includes some of those which target the nervous system such as Venezuelan Equine 
Encephalitis58 which was weaponised in the former US offensive biological weapons 
programme.  There is thus a distinct possibility that viral vectors could be found which would 
deliver bioregulators directly into the nervous system. 
 
What Should be Done? 
 
36. In a Congressional hearing59 on 5 February 2003, the US Secretary of Defense was asked 
a question about the possible use of a non-lethal technology in a war with Iraq.  The Secretary 
of State said that the US had signed a treaty, "tangled ourselves up so badly", that it was very 
difficult to write coherent rules of engagement for soldiers to use non-lethal riot control 
agents.  Indeed, Secretary Rumsfeld stated that he and his top commander had spent an hour 
or an hour and a half trying to write a set of such rules.   In his opinion, the issue was very 
complex and unfortunate because he believed there were many situations where is would be 
preferable to be able to use such riot control agents.  He cited, for example, attempting to 
remove a mixed crowd of combatants and non-combatants from a cave when US soldiers 
were being fired on from the cave. 
 
37. The reasons for these difficulties were discussed in some detail in a recent article60 by 
Major Ernest Harper of the US Marine Corps.  According to Harper the problem facing the 
Defense Secretary has long roots.  When negotiation of the Chemical Weapons Convention 
began in the early 1980s the US view was that riot control agents "did not constitute chemical 
weapons, due to their nonlethal nature".  Indeed, when President Ford acted in 1975 to ratify 
                                                 
53Bird, T. D. (2001)  Thoughts on the relationship of the Human Genome Project to neurology.  Archives of 
Neurology, 58 (11).   Available at  http://archneur.ama-assn.org/issues/v58n11/full/ned1003.html  
54Tsuji, S. (2001)  Neurogenetics in the postgenome era. Archives of Neurology, 58 (11).   Available at  
http://archneur.ama-assn.org/issues/v58n11/full/ned1006.html  
55Shapira, M. et al. (2000)  A transcription-activating polymorphism in the ACHE promoter associated with 
acute sensitivity to anti-acetylcholinesterases.  Hum. Mol. Genet., 9 (9), 1273-1278. 
56Bartfai, T. and Sellstrom, A. (2002)   Neurobiology, weapons, humanity.  Presentation at the ICRC   
Symposium on Biotechnology, Weapons and Humanity, Montreux, 23 September. 
57Brandes, A. A., Lacombe, D. and Vecht, C. (2001)  Future trends in the treatment of brain tumours.  European 
Journal of Cancer, 37 (18), 2297-2301. 
58Gubler, D. J. (2002)  The global emergence/resurgence of arboviral diseases as public health problems.  
Archives of Medical Research, 33 (4), 330-342. 
59Rumsfeld, D., Testimony to the U S House Armed Services Committee, 5 February 2003. Audio of testimony 
available at http://www.house.gov/hasc/schedules/2003.html#Feb03. Non-lethal weapons testimony starts at 1 hr 
32 minutes 45 seconds.   
60Harper, Major E. (2001)  A  call for a definition of a method of warfare in relation to the Chemical Weapons 
Convention.  Naval Law Review, XLVIII, 132-160. 
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the 1925 Geneva Protocol his Executive Order 1185061 allowed for specific exemptions that 
permitted the use of riot control agents such as for dealing with the kind of situations 
confronting the present-day US Secretary of Defense.  However, other parties to the CWC 
negotiations, including many of America's allies, wanted riot control agents included in the 
definition of chemical weapons because62: 
 
"They believed that any use of a RCA [riot control agent] could all too easily 
escalate to the use of lethal chemical weapons, and viewed RCAs as a large 
loophole in the effort to eradicate chemical warfare.  A loophole they were 
determined to close." 
 
According to Harper, in the endgame of the negotiations in the early 1990s neither side 
wished to give up its position but each wished to conclude the Convention.  Thus a  
compromise was reached in paragraph 5 of Article I which states that "Each State Party 
undertakes not to use riot control agents as a method of warfare".  In Harper's view this 
seemingly straightforward text is  "intentionally undefined and ambiguous" as it was 
designed as a compromise between two polarised positions.  His concern, given that the 
Senate enacted the exemptions of Executive Order 11850 when it ratified the Convention and 
that no reservations are allowed, is that US soldiers could end up being perceived as breaking 
international law.  His paper is therefore an attempt to clarify the meaning of "a method of 
warfare".  Recently released US military legal reviews63 have also attempted to show that 
common riot control agents are subject to a quite different legal regime than chemical 
weapons in the Chemical Weapons Convention on account of their limited physiological 
impact on the victim. 
 
38. Despite such complexities there is clearly evidence64 that the US military is still 
attempting to discover new forms of chemical incapacitant.   Moreover, some might argue 
that the peaceful purpose exemption of Article II.(9)(d) of the Chemical Weapons 
Convention, which allows for "Law enforcement including domestic riot control purposes", 
would allow quite new law enforcement chemicals with complex physiological effects on 
humans to be developed - particularly as no definition is offered for what chemicals are 
permitted for law enforcement other than that Schedule 1 chemicals may not be used. 
 
39. At the time of the negotiation of the Convention an editorial65 in the Chemical Weapons 
Convention Bulletin pointed out the dangers: 
 
"The Chemical Weapons Convention in no way limits use of tear gas or other 
temporarily disabling chemicals by police forces for purposes of domestic riot 
control.  But the language used to exempt other law enforcement purposes has 
created ambiguity in the heart of the Convention..."  [Emphasis added] 
 
                                                 
61US Executive Order 11850, Renunciation of certain uses in war of herbicides and riot control agents, 8 April 
1975.  Available at http://www.archives.gov/federal_register/codification/executive_order/11850.html 
62Harper, Major E. (2001)  A  call for a definition of a method of warfare in relation to the Chemical Weapons 
Convention.  Naval Law Review, XLVIII, 132-160. 
63Department of the Navy (1998) Legal Review of Oleoresin Capsicum (OC) Pepper Spray, (Ser 103/353).  
Office of the Judge Advocate General, Alexandria, Virginia. 
64Joint Non-Lethal Weapons Directorate (2003)   Front End Analysis for Non-lethal Chemicals.  Available at  
http://www.sunshine-project.org/publications/nlwdpdt/feachemical.jpg  
65Editorial (1994)  New technologies and the loophole in the Convention.  Chemical Weapons Convention 
Bulletin, 23, March, 1-2. 
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In particular, the editorial noted that: 
 
"What is at stake is the ability of the treaty regime to withstand technical 
change.  For new chemical agents and technologies have begun to emerge whose 
attractions for weapons purposes may eventually drive them through the 
loopholes which the ambiguity has created."  [Emphasis added] 
 
The evidence presented in this paper shows that we have now reached that point as, in regard 
to a number of systems that could well be of interest to those with a malign intent, it is 
clearly now possible to create specific chemicals that target specific receptor sub-types 
and thereby cause specific behavioural effects. 
 
40. It is certainly possible to find strong advocates of non-lethal chemical weapons who  
believe that it is necessary to consider selective changes to current international legal   
agreements.  As Fidler has noted66:  
 
"The selective change perspective uses changes in military operations and 
technologies as a basis for advocating selective, case-by-case reforms in 
international law to allow NLW [Non-Lethal Weapons] development and use..." 
 
But, he argued, inherent in that selective change position is a much more radical position that 
could upset the current international legal system that we have developed over centuries to 
constrain warfare.  He noted, for example, that: 
 
"Arguments in favour of developing and deploying NLWs often rely on the new 
capabilities such weapons give military forces and suggest that such capabilities 
affect how we evaluate the ethics of weapons' use..."  
 
As an example, at present soldiers are clearly not allowed to directly target civilians with their 
lethal weapons.  If we agree that civilians can be targeted directly with non-lethal weapons 
(when with such weapons there will always be a risk of deaths67) where does that leave the 
principle of discrimination between combatants and non-combatants? 
 
Conclusions 
 
41. With the extremely rapid current rate of development in the life sciences it would be 
dangerous to leave this matter unattended to at the 2003 Review Conference.  It is likely that 
the   scientific possibilities will be even more tempting to those seeking new weapon systems 
after five more years.  The bioregulators and synthetic analogues such as fentanyl considered 
here are mid-spectrum agents covered -- and correctly so -- by both the Biological and Toxin 
Weapons Convention and the Chemical Weapons Convention.  A NATO Advanced Research 
Workshop held in the run-up to the 2001 Review Conference of the Biological and Toxin 
Weapons Convention considered the scientific changes carefully and recognized that the 
                                                 
66Fidler, D. P. (2001)  "Non-lethal' weapons and international law: Three perspectives on the future.  Medicine, 
Conflict and Survival, 17, 194-206. 
67Klotz, L, Furmanski, M and Wheelis, Mark (2003) Beware the Siren's Song: Why "Non-Lethal" 
Incapacitating Chemical Agents are Lethal, Available at http://microbiology/ucdavis.edu.faculty/mwheelis/ 
sirens_song.pdf  
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scope of the Convention should be reaffirmed as at previous Review Conferences by a 
consensus statement in regard to Article I, along the following lines68. 
 
"The Conference...reaffirms that the Convention unequivocally covers all microbial 
or other biological agents or toxins, naturally or artificially created or altered, as 
well as their components, whatever their origin or method of production, of types and 
in quantities that have no justification for prophylactic, protective or other peaceful 
purposes.  Consequently, prions, proteins and bioregulators, and their synthetically 
produced analogues and components are covered." [Emphasis added] 
 
Unfortunately, no Final Declaration was agreed by the 2001-2002 Review Conference of the 
Biological and Toxin Weapons Convention and consequently the opportunity for such a 
consensus statement was missed. 
 
42. As was shown in our First CWC Review Conference Paper69 this system of reaffirmation 
and developed understanding of the scope of Biological and Toxin Weapons Convention has 
come about through the Final Declarations agreed at successive Review Conferences since 
1980.  There is much to be said for the Review Conferences of the Chemical Weapons 
Convention to gain similar benefits from extended understandings agreed in their Final 
Declarations.  Appropriate language would be to state that: 
 
"The Conference also reaffirms that the Convention unequivocally covers all 
chemicals, regardless of whether they are produced in facilities, in munitions or 
elsewhere, of types and in quantities that are consistent with purposes not 
prohibited under this Convention." 
 
In order to avoid any possible misunderstanding, it was suggested that an explanatory 
sentence should be added to state that: 
 
"Consequently, toxins, prions, proteins, peptides and bioregulators and their 
biologically or synthetically produced analogues and components are covered." 
[Emphasis added] 
 
43.  The Review Conference must address this issue to prevent a dangerous erosion of the 
purpose and objective of the Convention.  The risks are real as a recent US military legal 
review70 noted: 
 
"Convulsives and calmatives may rely on their toxic properties to have a 
physiological effect on humans.  If that is the case, and these two NLWs [Non-
Lethal Weapons] are not considered RCAs [Riot Control Agents], in order to 
avoid being classified as a prohibited chemical weapon, they would have to be 
used for the article I(9)(d) "purpose not prohibited" the law enforcement purpose.  
                                                 
68Pearson, G. S. (2002)  New Scientific and Technological Developments of Relevance to the Fifth BTWC 
Review Conference,  Review Conference Paper No. 3, University of Bradford, October.  Available at   
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Conference: The BTWC Review Conference Experience.  CWC Review Conference Paper, No. 1, University of 
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70Department of the Navy (1997) Preliminary Legal Review of Proposed Chemical-Based Nonlethal Weapons.  
Office of the Judge Advocate General (International and Operational Division), 30 November. Alexandria, 
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As discussed...the limits of this "purpose not prohibited" are not clear and will 
be determined by the practice of states." [Emphasis added] 
 
 If the Review Conference does not clearly address this issue novel non-lethal weapons based 
on the new understanding of the nervous system and its chemical neurotransmitters and 
receptors could well have been deployed and used before there is an opportunity for the next 
CWC Review Conference to address the issue. The events in Moscow in late 2002 would 
then be seen as a harbinger of a much more dangerous future with a seriously eroded 
chemical weapons prohibition regime rather than as an isolated hangover from the military 
developments of the Cold War period which has served as a useful signal to strengthen the 
understanding that all such chemicals are prohibited under the Chemical Weapons 
Convention. 
 
44.  Although it is true that the CWC is, in a sense, under continuous review through the 
annual Conferences of the States Parties and the regular Executive Council meetings, it 
would be irresponsible if the States Parties at the forthcoming Review Conference in April 
2003 -- given the mandate of the Review Conference specified in the Convention to convene 
in special sessions to undertake reviews of the operation of this Convention.  Such reviews 
shall take into account any relevant scientific and technological developments. -- were to fail 
to address the real and present danger to the Chemical Weapons Convention from 
incapacitating chemicals.   The outcome should be a clear reaffirmation of the comprehensive 
prohibition of toxic chemicals in the Convention making it clear in the reaffirmation that all 
incapacitating chemicals are covered.   Consideration could also be given to an action placed 
on the annual Conference of States Parties and the Executive Council to be vigilant to ensure 
that there is no erosion of the chemical weapons prohibition regime through incapacitating 
chemicals. 
 
 
